Amanta Healthcar

Which are the latest news on Amanta Healthcar?

Why is Amanta Healthcare Ltd falling/rising?

As of 05-Sep, Amanta Healthcare Ltd's stock price is rising to 194.80, with a 1.99% increase. The stock has shown strong performance, significantly outperforming the Sensex, and has seen increased investor interest despite some long-term fundamental concerns.

As of 05-Sep, Amanta Healthcare Ltd's stock price is rising, currently at 194.80, reflecting a change of 3.8 (1.99%) upward. The stock has shown strong performance over various periods, with a 6.13% increase over the past week and a notable 14.55% rise over the past month, significantly outperforming the Sensex, which has declined by 0.97% and 2.44% respectively during those periods. Year-to-date, the stock has surged by 79.21%, while the Sensex has fallen by 10.21%.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 2.44% and has experienced consecutive gains over the last two days, accumulating a total return of 4% in that timeframe. The stock's price has remained stable, trading consistently at the opening price of 194.80. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive indicator of its upward momentum.<BR><BR>Investor participation has also increased, with delivery volume rising by 121.06% compared to the 5-day average, suggesting growing interest in the stock. The liquidity is adequate for trading, supporting the stock's active market presence.<BR><BR>While there are some concerns regarding the company's long-term fundamental strength, including a weak EBIT to Interest ratio and low profitability per unit of shareholders' funds, the recent performance metrics and rising investor interest indicate a positive sentiment towards Amanta Healthcare Ltd, contributing to its rising stock price.

What does Amanta Healthcar do?

Amanta Healthcare Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of 69 Cr and a net profit of 3 Cr for June 2026. Originally incorporated in 1994, it has undergone several name changes, with its current name adopted in 2014.

Overview:<BR>Amanta Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1994 as Marck Parenterals (India) Limited. It underwent several name changes, becoming Marck Biosciences Limited in 2005 and finally Amanta Healthcare Limited in 2014. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 69 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 713 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 45.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.69 <BR>Return on Equity: 7.30% <BR>Price to Book: 3.24 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Amanta Healthcar?

Amanta Healthcar's peers include Kopran, Bharat Parenter., Wanbury, Anlon Healthcare, Anuh Pharma, Shree Ganesh Rem, Bafna Pharma, Zim Laboratories, and Kilitch Drugs. Management risk varies from excellent at Anlon Healthcare and Kilitch Drugs to below average at Bharat Parenter. and Bafna Pharma, with Bafna Pharma showing the highest 1-year return at 198.53%.

Peers: The peers of Amanta Healthcar are Kopran, Bharat Parenter., Wanbury, Anlon Healthcare, Anuh Pharma, Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, and Kilitch Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare and Kilitch Drugs, while Average management risk is found at Kopran, Wanbury, Zim Laboratories, and the rest. Below Average management risk is present at Bharat Parenter., Bafna Pharma., and Anuh Pharma. Growth is Excellent at Anlon Healthcare, Average at Kopran, Wanbury, Zim Laboratories, and Kilitch Drugs, and Below Average at Bharat Parenter., Shree Ganesh Rem, Bafna Pharma., Amanta Healthcar, Anuh Pharma, and the rest. Capital Structure is Excellent at Anuh Pharma and Shree Ganesh Rem, Good at Kopran and Kilitch Drugs, and Below Average at Bharat Parenter., Wanbury, Bafna Pharma., Amanta Healthcar, Zim Laboratories, and the rest.<BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 198.53%, while Wanbury has the lowest at -8.90%. Amanta Healthcar's 1-year return is not available for comparison. Additionally, peers with negative six-month returns include Wanbury and Bafna Pharma.

How big is Amanta Healthcar?

As of 31st August, Amanta Healthcare Ltd has a market capitalization of 713.00 Cr, with recent net sales of 291.17 Cr and a net profit of 14.68 Cr. Shareholder's funds are 220.21 Cr and total assets amount to 557.98 Cr as of March 2026.

As of 31st August, Amanta Healthcare Ltd has a market capitalization of 713.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Amanta Healthcare reported Net Sales of 291.17 Cr and a Net Profit of 14.68 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 220.21 Cr and Total Assets of 557.98 Cr.

Should I buy, sell or hold Amanta Healthcare Ltd?

When is the next results date for Amanta Healthcare Ltd?

The next results date for Amanta Healthcare Ltd is August 5, 2026.

The next results date for Amanta Healthcare Ltd is scheduled for August 5, 2026.

Are Amanta Healthcare Ltd latest results good or bad?

Amanta Healthcare Ltd's latest results show a mixed performance, with a net profit increase of 19.44% and revenue growth of 6.84%, but a decline in operating margins and ongoing operational challenges suggest the results are not entirely favorable. The company needs to address these issues for sustainable growth and profitability.

Amanta Healthcare Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹5.53 crores for Q4 FY26, which is a significant increase of 19.44% compared to the previous quarter. Additionally, revenue grew by 6.84% year-on-year, reaching ₹76.99 crores, marking the highest quarterly revenue in recent times.<BR><BR>However, there are notable concerns as well. The operating margin has declined to 19.42%, down from 20.62% in the previous quarter and significantly lower than 26.31% in the same quarter last year. This decline indicates potential challenges in pricing power or increased costs, which could affect profitability moving forward.<BR><BR>Moreover, while the company has shown some improvement in net profit, it remains below the previous year's figures, reflecting ongoing operational challenges. The average return on equity (ROE) of 8.18% and return on capital employed (ROCE) of 13.97% over the past five years suggest that the company is facing issues with capital efficiency and profitability.<BR><BR>In summary, while there are positive aspects such as revenue growth and improved net profit, the decline in margins and underlying operational challenges indicate that the results are not entirely favorable. The company is at a critical juncture, needing to address these issues to ensure sustainable growth and profitability.